We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: biomarkers
MedXY News
EnglishTag

biomarkers

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO
Critical CarebiomarkersECMO

Plasma GFAP and NfL Levels Predict Acute Brain Injury and Poor Outcomes in Pediatric ECMO

By MedXY|Mar 2, 2026

This multi-center study demonstrates that serial monitoring of plasma GFAP and NfL biomarkers can detect acute brain injury in pediatric ECMO patients before imaging diagnosis, significantly correlating with long-term survival and functiona

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO
Critical Carebiomarkersneurocritical care

Plasma GFAP and NfL as Real-Time Predictors of Brain Injury and Long-Term Disability in Pediatric ECMO

By MedXY|Mar 2, 2026

A prospective study demonstrates that rising levels of plasma GFAP and NfL precede neuroimaging-confirmed brain injury in children on ECMO. These biomarkers are also strongly associated with mortality and long-term functional impairment, of

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses
CardiologybiomarkersMendelian Randomization

Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses

By MedXY|Mar 2, 2026

A groundbreaking large-scale proteomic study identified 15 novel plasma markers for venous thromboembolism, highlighting biological pathways in extracellular matrix regulation and vascular senescence.

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision
Gastroenterologybiomarkersliver transplantation

Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision

By MedXY|Feb 21, 2026

Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially tr

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk
Cardiologybiomarkerscardiovascular disease

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

By MedXY|Feb 22, 2026

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional

Neurofilament Light Chain: A High-Performance Biomarker for Differentiating bvFTD from Primary Psychiatric Disorders
Neurologybiomarkersfrontotemporal dementia

Neurofilament Light Chain: A High-Performance Biomarker for Differentiating bvFTD from Primary Psychiatric Disorders

By MedXY|Feb 14, 2026

This systematic review confirms that Neurofilament Light Chain (NfL) in blood and CSF effectively distinguishes behavioral variant frontotemporal dementia from psychiatric disorders, offering a powerful tool for early and accurate diagnosis

LOAD Polygenic Risk in Early-Onset Alzheimer’s: Insights into Synaptic Dysfunction and Amyloid Pathophysiology
Neurologybiomarkerspolygenic risk score

LOAD Polygenic Risk in Early-Onset Alzheimer’s: Insights into Synaptic Dysfunction and Amyloid Pathophysiology

By MedXY|Feb 14, 2026

A comprehensive study explores how polygenic risk scores for late-onset Alzheimer’s disease (LOAD) influence early-onset (EOAD) cases. While these scores do not independently predict EOAD onset or cognitive decline, they reveal significant

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles
NeurologyAlzheimer's diseasebiomarkers

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

By MedXY|Feb 6, 2026

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
newsbiomarkers

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

By MedXY|Feb 2, 2026

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes
Cardiologyatrial fibrillationbiomarkers

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

By MedXY|Jan 22, 2026

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFp

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma
GastroenterologybiomarkersCytokines

CYTOscore: A Triple-Cytokine Signature Predicts Survival and Response to Chemoradiotherapy Plus Anti-PD-1 in Esophageal Squamous Cell Carcinoma

By MedXY|Jan 19, 2026

A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock
Cardiologybiomarkerscardiogenic shock

Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock

By MedXY|Jan 18, 2026

A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
Cardiologyatrial fibrillationbiomarkers

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

By MedXY|Jan 18, 2026

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients
Cardiologybiomarkersheart failure

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

By MedXY|Jan 17, 2026

A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles
newsbiomarkersimmunotherapy

Serplulimab Plus Chemotherapy Sustains Survival Advantage in ES-SCLC: Insights from the ASTRUM-005 Trial and Novel Biomarker Profiles

By MedXY|Jan 14, 2026

Updated ASTRUM-005 results confirm serplulimab’s significant survival benefit in extensive-stage small-cell lung cancer (15.8 vs. 11.1 months). Exploratory analyses identify a 15-protein signature and RB1/Notch mutations as potential

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial
newsBaricitinibbiomarkers

Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial

By MedXY|Jan 13, 2026

A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer
newsbiomarkersimmunotherapy

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

By MedXY|Jan 12, 2026

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
newsbiomarkersimmunotherapy

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

By MedXY|Jan 12, 2026

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease
Cardiologybiomarkerscardiovascular disease

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

By MedXY|Jan 9, 2026

Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency
NeurologyAlzheimer's diseasebiomarkers

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

By MedXY|Jan 7, 2026

A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and

Prev
3 / 5
12345
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities